A phase I clinical trial demonstrates that nfP2X7-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

British Journal of Dermatology

Volumn 177, Issue 1, 2017, Pages 117-124

  Gilbert, S M ^a   Gidley Baird, A ^b   Glazer, S ^c   Barden, J A ^b   Glazer, A ^c   Teh, L C ^b   King, J ^b  

^a Babraham Research Campus   (United Kingdom)

^b Cephalon Australia Pty Ltd   (Australia)

^c Glazer Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BIL010T; PROTEIN NFP2X7; PURINERGIC P2X RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOGLOBULIN G; P2XR RECEPTOR, HUMAN; PURINERGIC P2X7 RECEPTOR;

ADULT; AGED; ANTIGEN BINDING; APPLICATION SITE PAIN; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN DEFECT; SKIN EXFOLIATION; VERY ELDERLY; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; METABOLISM; MOUSE; SKIN TUMOR; TREATMENT OUTCOME; XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OINTMENTS; RECEPTORS, PURINERGIC P2X7; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 85020394196     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15364     Document Type: Article

References (31)

1. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep 2015; 7:53.
2. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88:167–79.
3. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990; 22:413–7.
4. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136:1524–30.
5. Mohan SV, Chang AL. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3:40–5.
6. 7). Science 1996; 272:735–8.
7. 7 (P2Z) receptor in CHO-K1 cells. Br J Pharmacol 1998; 125:1194–201.
8. Di Virgilio F, Chiozzi P, Falzoni S et al. Cytolytic P2X purinoceptors. Cell Death Differ 1998; 5:191–9.
9. Pellegatti P, Raffaghello L, Bianchi G et al. Increased level of extracellular ATP at tumour sites: in vivo imaging with plasma membrane luciferase. PLOS ONE 2008; 3:e2599.
10. Adinolfi E, Callegari MG, Ferrari D et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 2005; 16:3260–72.
11. 7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 2011; 30:2108–22.
12. 7 receptor increases in vivo tumour growth. Cancer Res 2012; 72:2957–69.
13. 7 reveals a key residue important for receptor function. Biochemistry 2010; 49:4611–9.
14. 7 receptor. J Biol Chem 2001; 276:11135–42.
15. 7 receptor. J Biol Chem 2003; 278:17108–13.
16. 7 receptor functions. J Psychiatr Res 2010; 44:347–55.
17. 7 ATP channel. Biochem Biophys Res Commun 2005; 332:17–27.
18. 7 receptor isoforms A and B in osteosarcoma. PLOS ONE 2014; 9:e107224.
19. 7 receptor through hetero-oligomerization. J Biol Chem 2006; 281:17228–37.
20. 7) pore formation. Am J Physiol Cell Physiol 2009; 297:C430–9.
21. 7 Receptor Diagnosis and Treatment of Cancers and Other Conditions. Patent WO2002057306 A1, 2002.
22. 7 Receptor, Diagnosis and Treatment of Cancers and Other Conditions. Patent WO2003020762 A1, 2003.
23. 7) receptors in HEK293 cells and B-lymphocytes. FEBS Lett 2003; 538:159–62.
24. 7 receptors. Histopathology 2004; 44:206–15.
25. Slater M, Danieletto S, Pooley M et al. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat 2004; 83:1–10.
26. Slater M, Scolyer RA, Gidley-Baird A et al. Increased expression of apoptotic markers in melanoma. Melanoma Res 2003; 13:137–45.
27. Barden JA, Yuksel A, Pedersen J et al. Non-functional P2X7: a novel and ubiquitous target in human cancer. J Clin Cell Immunol 2014; 5:237.
28. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendation for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289:1–16.
29. Greig AV, Linge C, Healy V et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol 2003; 121:315–27.
30. Hunt MJ, Halliday GM, Weedon D et al. Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol 1994; 130:1–8.
31. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006; 28:293–31.